INBX · Inhibrx Biosciences, Inc.

Inhibrx's updated interim data from the Phase 1/2 CRC cohort of ozekibart (INBRX-109) combined with FOLFIRI demonstrates a compelling efficacy signal in a challenging patient population, where approximately 70% were fourth-line and 80% had progressed on prior irinotecan regimens. The 20% ORR markedly exceeds historical standard-of-care benchmarks of 1-6%, with nearly half of responses durable beyond 6 months and activity seen across RAS/RAF statuses. Median PFS of 5.5 months, coupled with 42% progression-free at 6 months and 9 ongoing patients, indicates potential for meaningful disease control beyond the median. The robust 87% DCR further underscores tumor growth inhibition potential. Safety remains favorable, aligning with FOLFIRI's profile without added liver toxicity concerns in a liver-metastatic heavy group (68%). These results support advancing to first-line registrational intent via planned 2H 2026 FDA discussions, alongside exploring accelerated approval in fourth-line CRC and refractory Ewing sarcoma. The April 2026 chondrosarcoma BLA submission adds to ozekibart's regulatory momentum, highlighted by prior Fast Track and orphan designations. Corporate presentation updates provide deeper pipeline context, including INBRX-106 milestones, positioning Inhibrx for multiple 2026 catalysts.